• 04 Nov 2015

    PCSK9 Inhibitors: A New Class of LDL-C Lowering Treatments

    Remy Corvese, Senior Analyst, Zitter Health Insights

    Since their development in the late 1980s, Statins have remained the gold standard in treating and regulating cholesterol production. Blockbuster drugs such as Lipitor (atorvastatin) and Crestor (rosuvastatin) produced annual revenues of over $12B globally in the mid-2000s. However, this blog post will discuss the emergence of a unique alternative treatment in lowering LDL cholesterol […]

    read more
  • 24 Aug 2015

    Co-pay discount programs still in the cards

    Jacquelyn Cafasso, Senior Analyst, Zitter Health Insights

    Despite the backlash amongst health plans and pharmacy benefit managers (PBMs) when co-pay cards first arrived on the managed markets scene, discount programs are still a frequently cited topic during payer visits, according to Zitter Health Insight’s ongoing research on value added programs. Co-pay discount programs, also called ‘co-pay cards,’ ‘co-pay offset programs,’ or ‘co-pay […]

    read more
  • 03 Aug 2015

    Comparing Patient Challenges: Determining Unique and Universal Challenges to Prescription Adherence

    Jennifer Rawding, Senior Analyst, Zitter Health Insights

    In a previous blog post, we focused on the primary drivers of prescription abandonment for rheumatoid arthritis patients. But do these patients face different challenges than other patients? We’ll compare data from the Abandonment Insight Monitor’s recent survey of over 1,000 asthma, chronic obstructive pulmonary disease (COPD), hepatitis C (HCV), multiple sclerosis (MS), rheumatoid arthritis […]

    read more
  • 15 Jul 2015

    Trends in Psoriasis Payer Management

    Larisa Vulakh, Senior Analyst, Zitter Health Insights

    The psoriasis marketplace has grown significantly in the last couple of years with newer agents being approved. With a new set of biologics entering the market, psoriasis is quickly becoming a dynamic therapeutic area. The newest entrant into the psoriasis market, Novartis’ Cosentyx, was approved in January 2015. By targeting IL-7, Cosentyx’s unique mechanism of […]

    read more
  • 10 Jul 2015

    July 2015 Greater Data Granularity in Covered Lives

    ZHI, Zitter Health Insights

    As a part of Zitter Health Insights’ ongoing commitment to continuously improving its products, ZHI has expanded the covered lives granularity and is including more timely updates for greater accuracy. This lives enhancement also includes more detailed PBM information and is a value added service to our well regarded and widely accepted Policy & Access Tracking Tool.

    read more